-$0.51 Earnings Per Share Expected for Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) This Quarter
Wall Street brokerages expect Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) to post earnings per share of ($0.51) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Aeglea Bio Therapeutics’ earnings. The highest EPS estimate is ($0.40) and the lowest is ($0.58). Aeglea Bio Therapeutics reported earnings of ($0.54) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 5.6%. The firm is scheduled to announce its next quarterly earnings report on Thursday, November 14th.
According to Zacks, analysts expect that Aeglea Bio Therapeutics will report full year earnings of ($2.12) per share for the current year, with EPS estimates ranging from ($2.34) to ($1.81). For the next year, analysts expect that the company will post earnings of ($2.04) per share, with EPS estimates ranging from ($2.54) to ($1.26). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Aeglea Bio Therapeutics.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.07).
In other news, CEO Anthony G. Quinn purchased 31,905 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The shares were bought at an average cost of $6.16 per share, with a total value of $196,534.80. Following the completion of the transaction, the chief executive officer now directly owns 333,955 shares of the company’s stock, valued at $2,057,162.80. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Anthony G. Quinn purchased 26,592 shares of the company’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were purchased at an average cost of $6.77 per share, for a total transaction of $180,027.84. Following the completion of the transaction, the chief executive officer now directly owns 304,135 shares of the company’s stock, valued at $2,058,993.95. The disclosure for this purchase can be found here. Insiders acquired 85,921 shares of company stock worth $551,526 over the last ninety days. Insiders own 12.60% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace North America L.P. bought a new position in shares of Aeglea Bio Therapeutics during the first quarter valued at about $179,000. Marshall Wace LLP bought a new position in shares of Aeglea Bio Therapeutics during the first quarter valued at about $3,026,000. Rhumbline Advisers lifted its position in shares of Aeglea Bio Therapeutics by 11.9% during the first quarter. Rhumbline Advisers now owns 24,130 shares of the biotechnology company’s stock valued at $194,000 after purchasing an additional 2,559 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Aeglea Bio Therapeutics by 72.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 286,225 shares of the biotechnology company’s stock valued at $2,144,000 after purchasing an additional 119,904 shares in the last quarter. Finally, Franklin Street Advisors Inc. NC lifted its position in shares of Aeglea Bio Therapeutics by 50.0% during the first quarter. Franklin Street Advisors Inc. NC now owns 30,000 shares of the biotechnology company’s stock valued at $242,000 after purchasing an additional 10,000 shares in the last quarter. 65.86% of the stock is currently owned by institutional investors.
Shares of Aeglea Bio Therapeutics stock traded down $0.08 during trading hours on Wednesday, reaching $7.90. The company’s stock had a trading volume of 78,900 shares, compared to its average volume of 177,387. Aeglea Bio Therapeutics has a one year low of $5.99 and a one year high of $11.16. The stock has a market cap of $228.09 million, a P/E ratio of -3.71 and a beta of 1.02. The business has a fifty day simple moving average of $7.39. The company has a quick ratio of 8.44, a current ratio of 8.44 and a debt-to-equity ratio of 0.05.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
Featured Story: Analyzing a company’s cash flow statement
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.